Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration

Semin Ophthalmol. 2010 Jan-Mar;25(1-2):16-20. doi: 10.3109/08820538.2010.481508.

Abstract

The study aim was to evaluate the short-term safety and efficacy of pegaptanib sodium injections (Macugen, Eyetech Pharmaceuticals, Inc., New York, NY) in the compassionate-use therapy of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Intravitreal pegaptanib was used to treat 41 eyes in 40 patients with CNV. Injections were given every 6 weeks, and a minimum of three injections were planned. The mean change in BCVA for all lesions was a loss of 0.03 Snellen lines. Seven eyes (17.1%) gained more than 3 lines, three (7.31%) lost 6 lines or more, and in 75.6% the BCVA stabilized or improved.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Aptamers, Nucleotide / adverse effects
  • Aptamers, Nucleotide / therapeutic use*
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Compassionate Use Trials
  • Female
  • Fluorescein Angiography
  • Humans
  • Injections
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy*
  • Male
  • Middle Aged
  • Prospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity / physiology
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Aptamers, Nucleotide
  • pegaptanib